Whitehawk Therapeutics, Inc. WHWK
3.22 USD +0.09 (+2.88%)
At closeNov 9, 2026, 4:01 PM EST
3.22 0.00 0.00%
After hours · Nov 9, 4:01 PM ET
3.10 Day range 3.29
1.97 52-week range 5.50
- YTD
- +33.06%
- 1 year
- +55.56%
- Market cap
- 183.57M
- EPS (ttm)
- -1.14
- YTD return
- +33.06%
- 1-year return
- +55.56%
- Volume
- 1.15M
- Avg volume
- 341.69K
- Open
- 3.14
- Previous close
- 3.13
- Day's range
- 3.10 – 3.29
- 52-week range
- 1.97 – 5.50
5D -0.14 (-4.28%)
Financials — quick view
WHWK Revenue — quarterly 0
WHWK Net income — quarterly -16.64M
WHWK EPS — quarterly -0.20
News
Whitehawk Therapeutics Q3 EPS $(0.23) Misses $(0.21) Estimate 
Whitehawk Therapeutics Presents Two-Real World Analyses Supporting Mucin 16 
Stifel Initiates Coverage On Whitehawk Therapeutics with Buy Rating, Announces Price Target of $9 
Reported Sunday, Whitehawk's Real-World Data Show PTK7 Expression Remains Stable After Standard-Of-Care Therapies, Reinforcing Rationale For HWK-007 In EGFR Wild-Type NSCLC 
Whitehawk Therapeutics Q2 EPS $(0.20) Beats $(0.30) Estimate - Leerink Partners Initiates Coverage On Whitehawk Therapeutics with Outperform Rating, Announces Price Target of $9
- Whitehawk Therapeutics Files Prospectus For Resale Of 22,321,887 Shares Of Common Stock
Whitehawk Therapeutics Enters Into A New Option Agreement With Hangzhou DAC For Access To CPT113 For Use In Up To Five Additional ADC Programs; Phase 1 Dose-Escalation Trials Of HWK-007 And HWK-016 Are Currently Enrolling; HWK-007 Trials-In-Progress Poster To Be Presented At ASCO 
12 Health Care Stocks Moving In Wednesday's Intraday Session - Whitehawk Therapeutics Enters PIPE Financing With Expected Gross Proceeds Of ~$87.5M From Sale Of 4,330,866 Shares At $3.92 Per Share And Warrants To Purchase 17,991,021 Shares At $3.9199 Per Warrant
Your note
Sign in to keep a note on WHWK — it syncs with the Stock Master app.